Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.46 |
| ▸ | AHCY | P23526 | 1/20 | 0.45 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | AMD1 | P17707 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14946120 | 1.00 | ADORA2A (0.46) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL15930980 | 0.91 | ADORA2A (0.43) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL16489873 | 0.91 | ADORA2A (0.43) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL15723511 | 0.86 | ADORA2A (0.47) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL15305461 | 0.85 | PRMT5 (0.57) | ADORA2AADORA2BAHCYPRMT5WDR77 | |
| SCHEMBL18858889 | 0.82 | AHCY (0.41) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL14946103 | 0.81 | ADORA2A (0.42) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL14928579 | 0.81 | ADORA2A (0.42) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL20010218 | 0.80 | ADORA2A (0.45) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL15746179 | 0.80 | ADORA2A (0.43) | ADORA2AADORA2BAHCYDNMT1DNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125937-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNATX, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9878056-B2 | Modified polynucleotides for the production of cosmetic proteins and peptides | MODERNATX, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20180002393-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2018-01-04 | — | — | US | disclosed |
| US-20170368200-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2017-12-28 | — | — | US | disclosed |
| US-20170348436-A1 | IN VIVO PRODUCTION OF PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2017-12-07 | — | — | US | disclosed |
| US-9828416-B2 | Modified polynucleotides for the production of secreted proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9827332-B2 | Modified polynucleotides for the production of proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9814760-B2 | Modified polynucleotides for the production of biologics and proteins associated with human disease | MODERNATX, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9790531-B2 | Enzymes and polymerases for the synthesis of RNA | MODERNATX, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9782462-B2 | Modified polynucleotides for the production of proteins associated with human disease | MODERNATX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20140010861-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | modeRNA Therapeutics (US) | 2014-01-09 | — | — | US | disclosed |
| US-20130252281-A1 | FORMULATION AND DELIVERY OF PLGA MICROSPHERES | modeRNA Therapeutics (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130244279-A1 | FORMULATION AND DELIVERY OF PLGA MICROSPHERES | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244278-A1 | FORMULATION AND DELIVERY OF PLGA MICROSPHERES | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245107-A1 | DLIN-MC3-DMA LIPID NANOPARTICLE DELIVERY OF MODIFIED POLYNUCLEOTIDES | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130237594-A1 | SPLIT DOSE ADMINISTRATION | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130236974-A1 | METHOD FOR INCREASING THE PRODUCTION OF A PROTEIN OF INTEREST | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130236974-A1 | METHOD FOR INCREASING THE PRODUCTION OF A PROTEIN OF INTEREST | IGF2BP1, PHAX, IGF2BP2 | ADORA2A 2442/4885ADORA2B 3139/4885AHCY 2355/4885 |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | RNGTT, L3MBTL3, RNASE1 | ADORA2A 1186/4885ADORA2B 1723/4885AHCY 1303/4885 |
| US-20180125937-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | ADORA2A 244/4885ADORA2B 383/4885AHCY 1150/4885 |
| US-20130237594-A1 | SPLIT DOSE ADMINISTRATION | IGF2BP1, IGF2BP2, NSUN2 | ADORA2A 1826/4885ADORA2B 2510/4885AHCY 3875/4885 |
| US-20170368200-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | POLRMT, POLN, PHAX | ADORA2A 3570/4885ADORA2B 3596/4885AHCY 4213/4885 |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | ADORA2A 244/4885ADORA2B 383/4885AHCY 1150/4885 |
| US-20170348436-A1 | IN VIVO PRODUCTION OF PROTEINS | MSH2, POLRMT, POLN | ADORA2A 2122/4885ADORA2B 2787/4885AHCY 2392/4885 |
| US-20130245107-A1 | DLIN-MC3-DMA LIPID NANOPARTICLE DELIVERY OF MODIFIED POLYNUCLEOTIDES | NSUN3, PLIN3, MCOLN3 | ADORA2A 3324/4885ADORA2B 3295/4885AHCY 3442/4885 |
| US-20140010861-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | ADORA2A 3329/4885ADORA2B 3118/4885AHCY 3275/4885 |
| US-20180002393-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | MSH2, POLN, MSH6 | ADORA2A 3523/4885ADORA2B 3903/4885AHCY 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.